January 3, 2017 Licensing, IP, and Legal

GE Healthcare to commercialize Rapiscan® outside the US, Canada & Mexico for increased access to heart exams

CHALFONT ST. GILES, UK – 3 January, 2017 – GE Healthcare’s Life Sciences business announced today that it has acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside the USA, Canada and Mexico. GE Healthcare’s strong industry presence and existing customer and... Read more

May 31, 2016 Clinical Research/Diagn. M&A, Partnerships

GE Healthcare joins high-profile vaccine collaboration to explore vaccine self-sufficiency and pandemic preparedness in Saudi Arabia as part of 2030 Vision

CHALFONT ST. GILES, UK AND RIYADH, SAUDI ARABIA – 31 May 2016 – GE Healthcare is entering into a vaccine collaboration with the National Industrial Clusters Development Program (NICDP) under the Ministry of Energy, Industry and Mineral Resources, SaudiVax and King Saud University, to enable vaccine self-sufficiency and pandemic preparedness in the Kingdom of Saudi... Read more